311 related articles for article (PubMed ID: 12540902)
1. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.
Sánchez I; Mahlke C; Yuan J
Nature; 2003 Jan; 421(6921):373-9. PubMed ID: 12540902
[TBL] [Abstract][Full Text] [Related]
2. Effects of overexpression of huntingtin proteins on mitochondrial integrity.
Wang H; Lim PJ; Karbowski M; Monteiro MJ
Hum Mol Genet; 2009 Feb; 18(4):737-52. PubMed ID: 19039036
[TBL] [Abstract][Full Text] [Related]
3. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
Jana NR; Zemskov EA; Wang Gh ; Nukina N
Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
[TBL] [Abstract][Full Text] [Related]
4. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
[TBL] [Abstract][Full Text] [Related]
5. Polyglutamine disease: acetyltransferases awry.
Hughes RE
Curr Biol; 2002 Feb; 12(4):R141-3. PubMed ID: 11864588
[TBL] [Abstract][Full Text] [Related]
6. Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells.
Naphade S; Tshilenge KT; Ellerby LM
Neurotherapeutics; 2019 Oct; 16(4):979-998. PubMed ID: 31792895
[TBL] [Abstract][Full Text] [Related]
7. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders.
Ross CA
Neuron; 2002 Aug; 35(5):819-22. PubMed ID: 12372277
[TBL] [Abstract][Full Text] [Related]
8. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
9. Towards a transgenic model of Huntington's disease in a non-human primate.
Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
[TBL] [Abstract][Full Text] [Related]
10. Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease.
Lunkes A; Trottier Y; Fagart J; Schultz P; Zeder-Lutz G; Moras D; Mandel JL
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1013-9. PubMed ID: 10434300
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles.
Smith DL; Portier R; Woodman B; Hockly E; Mahal A; Klunk WE; Li XJ; Wanker E; Murray KD; Bates GP
Neurobiol Dis; 2001 Dec; 8(6):1017-26. PubMed ID: 11741397
[TBL] [Abstract][Full Text] [Related]
12. Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity.
Nucifora FC; Ellerby LM; Wellington CL; Wood JD; Herring WJ; Sawa A; Hayden MR; Dawson VL; Dawson TM; Ross CA
J Biol Chem; 2003 Apr; 278(15):13047-55. PubMed ID: 12464607
[TBL] [Abstract][Full Text] [Related]
13. Extended polyglutamine selectively interacts with caspase-8 and -10 in nuclear aggregates.
U M; Miyashita T; Ohtsuka Y; Okamura-Oho Y; Shikama Y; Yamada M
Cell Death Differ; 2001 Apr; 8(4):377-86. PubMed ID: 11550089
[TBL] [Abstract][Full Text] [Related]
14. Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions.
Bates GP; Davies SW
Mol Med Today; 1997 Nov; 3(11):508-15. PubMed ID: 9430787
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein.
Nucifora LG; Burke KA; Feng X; Arbez N; Zhu S; Miller J; Yang G; Ratovitski T; Delannoy M; Muchowski PJ; Finkbeiner S; Legleiter J; Ross CA; Poirier MA
J Biol Chem; 2012 May; 287(19):16017-28. PubMed ID: 22433867
[TBL] [Abstract][Full Text] [Related]
17. Lack of RAN-mediated toxicity in Huntington's disease knock-in mice.
Yang S; Yang H; Huang L; Chen L; Qin Z; Li S; Li XJ
Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4411-4417. PubMed ID: 32029588
[TBL] [Abstract][Full Text] [Related]
18. Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation.
Nozaki K; Onodera O; Takano H; Tsuji S
Neuroreport; 2001 Oct; 12(15):3357-64. PubMed ID: 11711886
[TBL] [Abstract][Full Text] [Related]
19. BAG-1 associates with the polyglutamine-expanded huntingtin aggregates.
Jana NR; Nukina N
Neurosci Lett; 2005 Apr; 378(3):171-5. PubMed ID: 15781153
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
